Ranibizumab

Active substance
Ranibizumab
Domain
Neurological disorders
Reason of inclusion in Horizonscan Geneesmiddelen
Biosimilar
Main indication
Eye disorders
Extended indication
Wet age-related macular degeneration (AMD).

1. Product

Current proprietary name
Lucentis (Novartis)
Proprietary name
PF582
Manufacturer
Hospira/Pfenex
Mechanism of action
Angiogenesis inhibitor
Budgetting framework
Intermural (MSZ)
Additional comments
Dit betreft 1 van de vier biosimilars voor ranibizumab die is opgenomen in de Horizonscan.

2. Registration

Registration route
Centralised (EMA)
Orphan drug
No
Registration phase
Clinical trials
Additional comments
Fase 1,2 studie afgerond in januari 2016 (NCT02121353). SPC Lucentis verloopt op 23 januari 2022.

3. Therapeutic value

Therapeutic value
Potential equal value
Duration of treatment
Not found

4. Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

5. Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

6. Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

There is currently nothing known about indication extensions.

9. Other information

There is currently no futher information available.